Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

NeuroScientific Biopharmaceuticals Ltd

NSB.AX ✗ NOT COMPLIANT ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.04

▼ -3.33%

Market Cap $15.94M · Vol 177.57K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$15.94M

Micro Cap

Div Yield

0.00%

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

38.89

Momentum

Beta

1.78

vs Market

52W High

$0.13

67.02% below

52W Low

$0.04

7.92% above

Volume

177.57K

Avg 171.75K

P/B

1.72

Price-to-book

ROE

N/A

Return on equity

Free Float

65.92%

Public shares

Shariah Compliance8 STANDARDS

✗ NeuroScientific Biopharmaceuticals Ltd (NSB.AX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NSB.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.69%

-10.77%

-42.00%

-55.38%

YTD

-47.27%

-69.47%

-27.66%

-79.65%

Financials & Valuation

TTM · Annual

Total Revenue	$109.28K
Net Income	$-1,214,343.00
Revenue Growth (YoY)	+358.57%
Gross Margin	100.00%
Operating Margin	-1,109.75%
Net Profit Margin	-1,111.23%
ROE	N/A
ROA · ROIC	-16.48% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	76.83
P/B	1.72
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	389.72M

Technical Indicators

50-Day SMA	$0.05
200-Day SMA	$0.07
RSI (14)	38.89
Beta	1.78
52-Week High	$0.13
52-Week Low	$0.04

Volume Today	177.57K
Avg Daily Volume (30D)	171.75K
Relative Volume	1.03x
Volatility (10D)	73.40
Volatility (30D)	78.65
Free Float	65.92%

Analyst Consensus

N/A

Current Price $0.04

Mean Target $0.31

52W Low$0.04 52W High$0.13

Current

Target

$0.04 $0.13

Current Analyst target

+645.78% upside potential · 0 analysts

Identifiers

ExchangeASX

FIGIBBG00KW6L707

ISINAU0000012973

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

NeuroScientific Biopharmaceuticals Limited is an Australia-based company, which is engaged in developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The Company's product portfolio includes EmtinB, a therapeutic peptide initially targeting glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn and EmtinBn). EmtinB is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury. Its StemSmart is a global patented technology engaged in manufacturing cell products. The use of its proprietary StemSmart technology in a special access program for fistulising Crohn’s disease.